Clearmind presents MEAI data at FDA forum

• Clearmind Medicine (NASDAQ:CMND) said its Chief of Global Impact Mary-Elizabeth Gifford addressed an FDA psychedelic medicine forum.
• The discussion focused on patient access and future therapeutic use of psychedelic drugs.
• Clearmind highlighted its FDA-approved clinical trial of MEAI for Alcohol Use Disorder.

Clearmind Medicine (NASDAQ:CMND) reported that its Chief of Global Impact Mary-Elizabeth Gifford participated in a U.S. Food and Drug Administration panel focused on potential future therapeutic use of psychedelic drugs.

The FDA-convened forum, titled “Considerations for Potential Future Therapeutic Use of Psychedelic Drugs,” brought together officials from the FDA, SAMHSA, NIH, NIDA, ARPA-H and the Veterans Health Administration, with about 1,800 participants attending in person and virtually.

Gifford addressed patient access considerations and discussed Clearmind’s proprietary non-hallucinogenic neuroplastogen MEAI, which is being studied in an FDA-approved clinical trial at Yale University Medical School and Johns Hopkins University.

Clearmind Medicine develops psychedelic-inspired compounds and therapeutic approaches targeting conditions including Alcohol Use Disorder and other health conditions.

The company said its research suggests next-generation compounds such as MEAI may support neuroplasticity without producing hallucinations, while further clinical evaluation will determine their potential applications.